Valeant Pharmaceuticals International, Inc. (VRX) Tops Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Aegis Capital Comments on Valeant Pharma (VRX) Following Q1 Results
May 8, 2014 9:46 AM EDTAegis Capital affirms Valeant Pharmaceuticals (NYSE: VRX) at Buy with a price target of $180 following Q1 results. Valeant reported Q1 EPS of $1.76,versus consensus views calling for EPS of $1.72. Revenue for the quarter came in at $1.85 billion, versus $1.04 billion reported last year.
Analyst Ram Selvaraju commented, We have slightly modified... More
